|
Gene: RPL34 |
Gene summary for RPL34 |
Gene summary. |
Gene information | Species | Human | Gene symbol | RPL34 | Gene ID | 6164 |
Gene name | ribosomal protein L34 | |
Gene Alias | L34 | |
Cytomap | 4q25 | |
Gene Type | protein-coding | GO ID | GO:0002181 | UniProtAcc | A0A024RDH8 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6164 | RPL34 | GSM4909281 | Human | Breast | IDC | 2.76e-60 | -3.39e-01 | 0.21 |
6164 | RPL34 | GSM4909282 | Human | Breast | IDC | 5.29e-79 | -4.28e-01 | -0.0288 |
6164 | RPL34 | GSM4909285 | Human | Breast | IDC | 3.42e-62 | -3.33e-01 | 0.21 |
6164 | RPL34 | GSM4909286 | Human | Breast | IDC | 6.63e-11 | 1.24e-01 | 0.1081 |
6164 | RPL34 | GSM4909287 | Human | Breast | IDC | 7.62e-03 | -1.12e-01 | 0.2057 |
6164 | RPL34 | GSM4909290 | Human | Breast | IDC | 1.13e-54 | -4.13e-01 | 0.2096 |
6164 | RPL34 | GSM4909293 | Human | Breast | IDC | 1.27e-49 | -2.59e-01 | 0.1581 |
6164 | RPL34 | GSM4909294 | Human | Breast | IDC | 4.57e-13 | -1.80e-01 | 0.2022 |
6164 | RPL34 | GSM4909295 | Human | Breast | IDC | 1.24e-11 | -2.74e-01 | 0.0898 |
6164 | RPL34 | GSM4909297 | Human | Breast | IDC | 5.69e-04 | -1.00e-01 | 0.1517 |
6164 | RPL34 | GSM4909299 | Human | Breast | IDC | 8.93e-13 | 1.35e-01 | 0.035 |
6164 | RPL34 | GSM4909302 | Human | Breast | IDC | 1.28e-16 | -2.17e-01 | 0.1545 |
6164 | RPL34 | GSM4909304 | Human | Breast | IDC | 1.76e-44 | -2.45e-01 | 0.1636 |
6164 | RPL34 | GSM4909307 | Human | Breast | IDC | 1.54e-38 | -2.41e-01 | 0.1569 |
6164 | RPL34 | GSM4909308 | Human | Breast | IDC | 7.48e-64 | -3.62e-01 | 0.158 |
6164 | RPL34 | GSM4909315 | Human | Breast | IDC | 2.35e-41 | -3.43e-01 | 0.21 |
6164 | RPL34 | GSM4909316 | Human | Breast | IDC | 2.92e-27 | -4.99e-01 | 0.21 |
6164 | RPL34 | GSM4909317 | Human | Breast | IDC | 1.97e-20 | -2.09e-01 | 0.1355 |
6164 | RPL34 | GSM4909318 | Human | Breast | IDC | 3.55e-07 | -3.28e-01 | 0.2031 |
6164 | RPL34 | GSM4909319 | Human | Breast | IDC | 4.25e-19 | -3.20e-01 | 0.1563 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000218113 | Lung | AIS | cytoplasmic translation | 85/1849 | 148/18723 | 5.48e-47 | 3.19e-43 | 85 |
GO:000218120 | Oral cavity | OSCC | cytoplasmic translation | 133/7305 | 148/18723 | 1.94e-38 | 2.46e-35 | 133 |
GO:0002181110 | Oral cavity | LP | cytoplasmic translation | 124/4623 | 148/18723 | 5.09e-52 | 3.19e-48 | 124 |
GO:000218126 | Oral cavity | EOLP | cytoplasmic translation | 102/2218 | 148/18723 | 7.91e-60 | 4.74e-56 | 102 |
GO:000218134 | Oral cavity | NEOLP | cytoplasmic translation | 102/2005 | 148/18723 | 3.70e-64 | 2.20e-60 | 102 |
GO:000218118 | Prostate | BPH | cytoplasmic translation | 115/3107 | 148/18723 | 1.08e-60 | 6.68e-57 | 115 |
GO:000218119 | Prostate | Tumor | cytoplasmic translation | 115/3246 | 148/18723 | 1.36e-58 | 8.43e-55 | 115 |
GO:000218128 | Skin | AK | cytoplasmic translation | 101/1910 | 148/18723 | 5.98e-65 | 3.54e-61 | 101 |
GO:0002181112 | Skin | SCCIS | cytoplasmic translation | 58/919 | 148/18723 | 2.30e-37 | 1.22e-33 | 58 |
GO:000218129 | Skin | cSCC | cytoplasmic translation | 127/4864 | 148/18723 | 4.83e-53 | 7.57e-50 | 127 |
GO:00021816 | Stomach | GC | cytoplasmic translation | 62/1159 | 148/18723 | 5.06e-36 | 2.75e-32 | 62 |
GO:000218111 | Stomach | CAG with IM | cytoplasmic translation | 61/1050 | 148/18723 | 1.99e-37 | 1.06e-33 | 61 |
GO:000218121 | Stomach | CSG | cytoplasmic translation | 62/1034 | 148/18723 | 6.36e-39 | 3.36e-35 | 62 |
GO:000218131 | Stomach | CAG | cytoplasmic translation | 60/552 | 148/18723 | 9.60e-53 | 4.29e-49 | 60 |
GO:000218141 | Stomach | WIM | cytoplasmic translation | 50/426 | 148/18723 | 4.78e-45 | 1.90e-41 | 50 |
GO:000218151 | Stomach | SIM | cytoplasmic translation | 61/708 | 148/18723 | 1.54e-47 | 7.28e-44 | 61 |
GO:000218130 | Thyroid | HT | cytoplasmic translation | 92/1272 | 148/18723 | 1.18e-69 | 6.57e-66 | 92 |
GO:0002181113 | Thyroid | PTC | cytoplasmic translation | 121/5968 | 148/18723 | 4.32e-36 | 4.54e-33 | 121 |
GO:0002181210 | Thyroid | goiters | cytoplasmic translation | 73/497 | 148/18723 | 1.65e-75 | 6.83e-72 | 73 |
GO:000218135 | Thyroid | ATC | cytoplasmic translation | 121/6293 | 148/18723 | 1.41e-33 | 1.49e-30 | 121 |
Page: 1 2 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0301018 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0301019 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0301024 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
hsa0517124 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0301034 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
hsa0517134 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0301044 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
hsa0517144 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
hsa0301054 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
hsa0517154 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RPL34 | SNV | Missense_Mutation | c.325N>A | p.Ala109Thr | p.A109T | P49207 | protein_coding | tolerated(0.11) | benign(0.003) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RPL34 | SNV | Missense_Mutation | rs780481231 | c.263N>A | p.Arg88His | p.R88H | P49207 | protein_coding | tolerated(0.15) | benign(0.001) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RPL34 | SNV | Missense_Mutation | rs374098934 | c.277C>T | p.Arg93Cys | p.R93C | P49207 | protein_coding | tolerated(0.05) | benign(0) | TCGA-BS-A0UJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RPL34 | SNV | Missense_Mutation | novel | c.86N>T | p.Arg29Ile | p.R29I | P49207 | protein_coding | deleterious(0.04) | benign(0.074) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
RPL34 | SNV | Missense_Mutation | novel | c.292N>A | p.Glu98Lys | p.E98K | P49207 | protein_coding | deleterious(0.05) | benign(0.003) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
RPL34 | SNV | Missense_Mutation | c.91N>A | p.Val31Ile | p.V31I | P49207 | protein_coding | tolerated(0.08) | benign(0.031) | TCGA-86-A4P7-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
RPL34 | SNV | Missense_Mutation | novel | c.46N>A | p.Ala16Thr | p.A16T | P49207 | protein_coding | tolerated(0.36) | benign(0.377) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
RPL34 | SNV | Missense_Mutation | c.218N>G | p.His73Arg | p.H73R | P49207 | protein_coding | tolerated(0.84) | possibly_damaging(0.602) | TCGA-BR-4361-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |